HIF2 inactivation and tumor suppression with a tumor-directed RNA-silencing drug in mice and humans

CONCLUSIONS: To our knowledge, this is the first example of functional inactivation of an oncoprotein and tumor suppression with a systemic, tumor-directed, RNA-silencing drug. These studies provide a proof-of-principle of HIF2α inhibition by RNA-targeting drugs in ccRCC and establish a paradigm for tumor-directed RNA-based therapeutics in cancer.PMID:36190432 | DOI:10.1158/1078-0432.CCR-22-0963

Source: Clinical Cancer Research - October 3, 2022 Category: Cancer & Oncology Authors: Yuanqing Ma Allison Joyce Olivia Brandenburg Faeze Saatchi Christina Stevens Vanina Toffessi Tcheuyap Alana Christie Quyen Do Oluwatomilade Fatunde Alyssa Macchiaroli So C Wong Layton Woolford Qurratulain Yousuf Jeffrey Miyata Deyssy Carrillo Oreoluwa Ona Source Type: research